Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0AG8L
|
|||
| Drug Name |
BMS-986231
|
|||
| Synonyms |
N-Hydroxy-5-methylfuran-2-sulfonamide; Cimlanod; Cimlanod [USAN]; UNII-2US4FK1EPV; 2US4FK1EPV; SCHEMBL15878610; LIXKIXWSKOENAB-UHFFFAOYSA-N; ZINC145617689; 2-Furansulfonamide, N-hydroxy-5-methyl-; 1620330-72-4
Click to Show/Hide
|
|||
| Indication | Acute decompensated heart failure [ICD-11: BD1Z; ICD-10: I50, I50.9; ICD-9: 428] | Phase 2 | [1] | |
| Acute heart failure [ICD-11: BD10-BD13; ICD-9: 428] | Phase 2 | [2] | ||
| Company |
Bristol-Myers Squibb Princeton, NJ
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C5H7NO4S
|
|||
| Canonical SMILES |
CC1=CC=C(O1)S(=O)(=O)NO
|
|||
| InChI |
1S/C5H7NO4S/c1-4-2-3-5(10-4)11(8,9)6-7/h2-3,6-7H,1H3
|
|||
| InChIKey |
LIXKIXWSKOENAB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1620330-72-4
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02157506) A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.